Avalo Therapeutics, Inc. · NASDAQ:AVTX

Sullivan Christopher Ryan sold 18,606 Avalo Therapeutics, Inc. shares (Form 4)

Traded May 7, 2026 · Filed May 11, 2026

On May 7, 2026, Sullivan Christopher Ryan (Chief Financial Officer) sold 18,606 Avalo Therapeutics, Inc. shares at US$24.12 for US$449K under a trading plan, leaving 423 shares. Filed May 11, 2026 (Form 4).

Sold
18,606 shares
Price
US$24.12
Value
US$449K
Holding after
423 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Financial Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
May 7, 2026Common StockOption exercise18,606US$9.8819,029Direct
May 7, 2026Common StockSale18,606US$24.12423Direct

Source

View original at SEC

Related